Table 1.
Baseline characteristics of the study population (n = 203) based on clinical diagnosis. Values are listed as the mean (± standard deviation) and dichotomous data as n (%)
| Total population n = 203 | |||
|---|---|---|---|
| Non-converted SCD | SCD to MCI/AD | p value | |
| Characteristics | n = 180 (89%) | n = 23 (11%) | |
| Age, year | 60 (±9) | 67 (±8) | < 0.001 |
| Female | 74 (41%) | 14 (61%) | 0.072 |
| MMSE | 28 (±1) | 28 (±1) | 0.036 |
| APOE ε4 carrier (reported) | 61 (34%) | 16 (70%) | < 0.001 |
| ε4 homozygotes | 51 (84%) | 12 (75%) | – |
| ε4 heterozygotes | 10 (16%) | 4 (25%) | – |
| Follow-up duration, y | 2.7 (±2.1) | – | – |
| Time to progression, y | – | 2.5 (±2.2) | – |
| CSF Aβ42, pg/ml | 1053 (±246) | 800 (±203) | < 0.001 |
| Plasma Aβ40, pg/ml | 208 (± 36) | 203 (±34) | 0.346 |
| Plasma Aβ42, pg/ml | 10 (±2) | 9 (±2) | 0.003 |
| Plasma Aβ42/40 ratio | 49 (±7) | 44 (±7) | 0.002 |
Abbreviations: MCI mild cognitive impairment, MMSE Mini-Mental State Examination, SCD subjective cognitive decline